Core Insights - Liquidia Corporation is hosting its first Research & Development Day on October 28, 2025, in New York City, focusing on innovative therapies for rare cardiopulmonary diseases [1][3] Group 1: Event Details - The R&D Day will feature presentations from Liquidia's management and key opinion leaders in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] - The agenda will include updates on L606, an investigational sustained-release formulation, and the flagship product YUTREPIA™ [2][3] - The event is intended for institutional investors and sell-side analysts, with options for in-person attendance and live webcasting [3][4] Group 2: Product Information - L606 is a twice-daily administered investigational formulation of treprostinil, utilizing a proprietary liposomal formulation for controlled drug release [5] - YUTREPIA is an inhaled dry-powder formulation of treprostinil designed for improved exercise ability in patients with PAH and PH-ILD, developed using Liquidia's PRINT® technology [6][7] - Liquidia is also marketing Treprostinil Injection, a fully substitutable generic of Remodulin for PAH treatment [7]